Ultragenyx Pharmaceutical Inc. (RARE) CEO Emil Kakkis on Q3 2019 Results - Earnings Call TranscriptSeeking Alpha • 11/06/19
Ultragenyx Announces FDA Accepts New Drug Application for UX007 (triheptanoin) for Treatment of Long-chain Fatty Acid Oxidation DisordersGlobeNewsWire • 10/14/19
Ultragenyx and Kyowa Kirin Announce U.S. FDA Approves Label Update for Crysvita® (burosumab) for the Treatment of X-Linked Hypophosphatemia (XLH)GlobeNewsWire • 09/30/19
Ultragenyx Pharmaceutical And Ultra-Rare Diseases: A Voice For The Clinically UnderservedSeeking Alpha • 09/23/19
Ultragenyx Pharmaceuticals And Ultra-Rare Diseases: A Voice For The Clinically UnderservedSeeking Alpha • 09/23/19
Ultragenyx and Kyowa Kirin Announce Intent to Submit Supplemental Biologics License Application to U.S. FDA for Crysvita® (burosumab) in Tumor-Induced Osteomalacia (TIO)GlobeNewsWire • 09/10/19
Ultragenyx Announces Positive Data from Phase 1/2 Study of DTX401 Gene Therapy in Glycogen Storage Disease Type IaGlobeNewsWire • 09/04/19
GeneTx and Ultragenyx Announce Orphan Drug Designation and Rare Pediatric Disease Designation for GTX-102GlobeNewsWire • 09/03/19
Ultragenyx (RARE) Down 9.9% Since Last Earnings Report: Can It Rebound?Zacks Investment Research • 08/31/19
This Biotech Stock Just Roped In A New Partner — And A Potential BuyoutInvestors Business Daily • 08/15/19
Ultragenyx Pharmaceutical Inc. (RARE) CEO Emil Kakkis on Q2 2019 Results - Earnings Call TranscriptSeeking Alpha • 08/02/19
Ultragenyx (RARE) May Report Negative Earnings: Know the Trend Ahead of Next Week's ReleaseZacks Investment Research • 07/25/19
Ultragenyx (RARE) Down 5.7% Since Last Earnings Report: Can It Rebound?Zacks Investment Research • 06/05/19
Ultragenyx Pharmaceutical Inc.'s (RARE) CEO Emil Kakkis on Q1 2019 Results - Earnings Call TranscriptSeeking Alpha • 05/07/19